US-headquartered drug development and manufacturing services provider JSR Life Sciences launched a corporate venture capital vehicle yesterday dubbed JSR Life Sciences Corporate Venture Fund.
The fund will be headed by Jason Yuanxin Zhang and will back companies developing innovative life sciences technology that can support pharmaceutical research, development and manufacturing. JSR led a $10.4m round for biomanufacturing technology developer AbSci in January 2020.
Jean-Pierre Wery, JSR Life Sciences’ chief technology officer, said: “Initiating this fund and offering the ability to invest in the life sciences sector is a natural extension of our core expertise.
“Jason’s ability to connect with contacts in many different facets of our industry, along with his experience in forging relationships and identifying promising assets, make him optimally qualified to identify opportunities for long-term value in our industry.”
